In December 2019, an outbreak caused by novel coronavirus 2019 (COVID-19) started in Wuhan, China. After extensive speculation about a causative agent, a novel betacoronavirus, in the same family as SARS-CoV and MERS-CoV, was identified via next-generation sequencing from samples received from several pneumonia patients. Ribonucleic acid extracted from the patient's bronchoalveolar lavage fluid was used as a template to clone and sequence the genome of SARS-CoV-2. Shortly after, the World Health Organization announced a worldwide pandemic. However, later reports revealed that the COVID-19 pathogen has a genetic footprint that had never been observed in natural coronavirus, suggesting a "gain of function virus" that might have been engineered in a laboratory. Clear conclusions about the outbreak's origins are still lacking. Theories regarding most probable wildlife animal reservoir for the SARS-CoV-2 have been scientifically shaky. Exactly how the virus jumped from wild animals to humans remains a mystery. Onging debate coalesces around 2 competing theories: laboratory accidental versus intentional escape scenario of a genetically engineered virus versus zoonotic emergence. Within a year after the declaration of the COVID-19 pandemic, Pfizer-BioNTech and Moderna published their 2-month duration follow-up mRNA vaccine trial results. Later reports revealed a rapidly declining vaccineinduced immunity, questionable effectiveness of these vaccines against the new variants despite boosting, inability to stop viral transmission, and, most importantly, the onset of serious adverse events. In the 2 context of all these uncertainties, controversies, and the remaining many unanswered questions, this first review presents a different perspective on the origin of the COVID-19 pandemic. A later analysis will address the subsequent events that followed in terms of diagnosis, protective measures, vaccines roll-out and vaccine mandate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.6002/ect.2023.0074 | DOI Listing |
J Med Internet Res
January 2025
Cancer Rehabilitation and Survivorship, Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Background: Virtual follow-up (VFU) has the potential to enhance cancer survivorship care. However, a greater understanding is needed of how VFU can be optimized.
Objective: This study aims to examine how, for whom, and in what contexts VFU works for cancer survivorship care.
PLoS One
January 2025
Department and Faculty of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
In Spain, the agricultural sector relies heavily on migrant workers, especially during seasonal seasons. However, these workers face significant challenges related to precarious working conditions and structural vulnerability, which have become more acute since the outbreak of the COVID-19 pandemic. This descriptive qualitative study was based on 87 personal interviews with health and social professionals from sectors such as NGOs, social services, trade unions, local institutions, and health services to promote compliance with these measures in four Spanish regions.
View Article and Find Full Text PDFPLoS One
January 2025
General Directorate of Infection Prevention & Control, Ministry of Health-Saudi Arabia, Riyadh, Saudi Arabia.
Background: Candida auris (C. auris) is an emerging fungus pathogen associated with nosocomial infections that is seen as a serious global health issue.
Aim: To describe the epidemiology and features of hospital-acquired Candida auris outbreaks in the Ministry of Health hospitals (MOH).
PLoS One
January 2025
Immunology and Immunotherapy Division, Center of Molecular Immunology (CIM), Havana, Cuba.
SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has triggered several therapeutic strategies against COVID-19 relying on the use of ACE2 recombinant proteins as decoy receptors. In this work, we propose an ACE2 silent Fc fusion protein (ACE2-hFcLALA) as a candidate therapy against COVID-19.
View Article and Find Full Text PDFPLoS One
January 2025
Kyiv School of Economics, Kyiv, Ukraine.
Based on nationally representative panel data (N person-years = 40,020; N persons = 18,704; Panel Labour Market and Social Security; PASS) from 2018 to 2022, we investigate how mental health changed during and after the COVID-19 pandemic. We employ time-distributed fixed effects regressions to show that mental health (Mental Health Component Summary Score of the SF-12) decreased from the first COVID-19 wave in 2020 onward, leading to the most pronounced mental health decreases during the Delta wave, which began in August 2021. In the summer of 2022, mental health had not returned to baseline levels.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!